323 related articles for article (PubMed ID: 21164517)
1. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.
Scuto A; Krejci P; Popplewell L; Wu J; Wang Y; Kujawski M; Kowolik C; Xin H; Chen L; Wang Y; Kretzner L; Yu H; Wilcox WR; Yen Y; Forman S; Jove R
Leukemia; 2011 Mar; 25(3):538-50. PubMed ID: 21164517
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo.
Yan S; Li Z; Thiele CJ
Oncotarget; 2013 Mar; 4(3):433-45. PubMed ID: 23531921
[TBL] [Abstract][Full Text] [Related]
3. AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway.
Wang SW; Hu J; Guo QH; Zhao Y; Cheng JJ; Zhang DS; Fei Q; Li J; Sun YM
Oncol Rep; 2014 Nov; 32(5):1991-8. PubMed ID: 25216185
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.
Gu L; Liao Z; Hoang DT; Dagvadorj A; Gupta S; Blackmon S; Ellsworth E; Talati P; Leiby B; Zinda M; Lallas CD; Trabulsi EJ; McCue P; Gomella L; Huszar D; Nevalainen MT
Clin Cancer Res; 2013 Oct; 19(20):5658-74. PubMed ID: 23942095
[TBL] [Abstract][Full Text] [Related]
5. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.
Hedvat M; Huszar D; Herrmann A; Gozgit JM; Schroeder A; Sheehy A; Buettner R; Proia D; Kowolik CM; Xin H; Armstrong B; Bebernitz G; Weng S; Wang L; Ye M; McEachern K; Chen H; Morosini D; Bell K; Alimzhanov M; Ioannidis S; McCoon P; Cao ZA; Yu H; Jove R; Zinda M
Cancer Cell; 2009 Dec; 16(6):487-97. PubMed ID: 19962667
[TBL] [Abstract][Full Text] [Related]
6. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
Li J; Favata M; Kelley JA; Caulder E; Thomas B; Wen X; Sparks RB; Arvanitis A; Rogers JD; Combs AP; Vaddi K; Solomon KA; Scherle PA; Newton R; Fridman JS
Neoplasia; 2010 Jan; 12(1):28-38. PubMed ID: 20072651
[TBL] [Abstract][Full Text] [Related]
7. AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.
Couto JP; Almeida A; Daly L; Sobrinho-Simões M; Bromberg JF; Soares P
PLoS One; 2012; 7(10):e46869. PubMed ID: 23056499
[TBL] [Abstract][Full Text] [Related]
8. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
[TBL] [Abstract][Full Text] [Related]
9. Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth.
Gritsina G; Xiao F; O'Brien SW; Gabbasov R; Maglaty MA; Xu RH; Thapa RJ; Zhou Y; Nicolas E; Litwin S; Balachandran S; Sigal LJ; Huszar D; Connolly DC
Mol Cancer Ther; 2015 Apr; 14(4):1035-47. PubMed ID: 25646015
[TBL] [Abstract][Full Text] [Related]
10. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells.
Pedranzini L; Dechow T; Berishaj M; Comenzo R; Zhou P; Azare J; Bornmann W; Bromberg J
Cancer Res; 2006 Oct; 66(19):9714-21. PubMed ID: 17018630
[TBL] [Abstract][Full Text] [Related]
11. Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.
Burger R; Le Gouill S; Tai YT; Shringarpure R; Tassone P; Neri P; Podar K; Catley L; Hideshima T; Chauhan D; Caulder E; Neilan CL; Vaddi K; Li J; Gramatzki M; Fridman JS; Anderson KC
Mol Cancer Ther; 2009 Jan; 8(1):26-35. PubMed ID: 19139110
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.
Suryani S; Bracken LS; Harvey RC; Sia KC; Carol H; Chen IM; Evans K; Dietrich PA; Roberts KG; Kurmasheva RT; Billups CA; Mullighan CG; Willman CL; Loh ML; Hunger SP; Houghton PJ; Smith MA; Lock RB
Mol Cancer Ther; 2015 Feb; 14(2):364-74. PubMed ID: 25504635
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480.
Xin H; Herrmann A; Reckamp K; Zhang W; Pal S; Hedvat M; Zhang C; Liang W; Scuto A; Weng S; Morosini D; Cao ZA; Zinda M; Figlin R; Huszar D; Jove R; Yu H
Cancer Res; 2011 Nov; 71(21):6601-10. PubMed ID: 21920898
[TBL] [Abstract][Full Text] [Related]
14. The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.
Stubbs MC; Burn TC; Sparks R; Maduskuie T; Diamond S; Rupar M; Wen X; Volgina A; Zolotarjova N; Waeltz P; Favata M; Jalluri R; Liu H; Liu XM; Li J; Collins R; Falahatpisheh N; Polam P; DiMatteo D; Feldman P; Dostalik V; Thekkat P; Gardiner C; He X; Li Y; Covington M; Wynn R; Ruggeri B; Yeleswaram S; Xue CB; Yao W; Combs AP; Huber R; Hollis G; Scherle P; Liu PCC
Clin Cancer Res; 2019 Jan; 25(1):300-311. PubMed ID: 30206163
[TBL] [Abstract][Full Text] [Related]
15. A novel small molecule agent displays potent anti-myeloma activity by inhibiting the JAK2-STAT3 signaling pathway.
Zhang Z; Mao H; Du X; Zhu J; Xu Y; Wang S; Xu X; Ji P; Yu Y; Cao B; Han K; Hou T; Xu Z; Kong Y; Jiang G; Tang X; Qiao C; Mao X
Oncotarget; 2016 Feb; 7(8):9296-308. PubMed ID: 26814430
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic inhibition of Jak activity inhibits progression of gastrointestinal tumors in mice.
Stuart E; Buchert M; Putoczki T; Thiem S; Farid R; Elzer J; Huszar D; Waring PM; Phesse TJ; Ernst M
Mol Cancer Ther; 2014 Feb; 13(2):468-74. PubMed ID: 24398427
[TBL] [Abstract][Full Text] [Related]
17. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
de Oliveira MB; Fook-Alves VL; Eugenio AIP; Fernando RC; Sanson LFG; de Carvalho MF; Braga WMT; Davies FE; Colleoni GWB
Cancer Lett; 2017 Sep; 403():206-215. PubMed ID: 28645562
[TBL] [Abstract][Full Text] [Related]
18. Decursin chemosensitizes human multiple myeloma cells through inhibition of STAT3 signaling pathway.
Kim HJ; Kim SM; Park KR; Jang HJ; Na YS; Ahn KS; Kim SH; Ahn KS
Cancer Lett; 2011 Feb; 301(1):29-37. PubMed ID: 21122982
[TBL] [Abstract][Full Text] [Related]
19. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway.
Chatterjee M; Hönemann D; Lentzsch S; Bommert K; Sers C; Herrmann P; Mathas S; Dörken B; Bargou RC
Blood; 2002 Nov; 100(9):3311-8. PubMed ID: 12384432
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of AZD1480 for the treatment of human glioblastoma.
McFarland BC; Ma JY; Langford CP; Gillespie GY; Yu H; Zheng Y; Nozell SE; Huszar D; Benveniste EN
Mol Cancer Ther; 2011 Dec; 10(12):2384-93. PubMed ID: 22027691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
